Noopur Raje, MD, Massachusetts General Hospital

Articles

Future of BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

Bispecific Antibodies for Multiple Myeloma

July 17th 2020

Differentiating among CAR T Products for Multiple Myeloma

July 17th 2020

Development of CAR T Cells in Multiple Myeloma

July 17th 2020

Using Antibody-Drug Conjugates in Multiple Myeloma

July 17th 2020

BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

July 17th 2020

BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

July 17th 2020

Lenalidomide-Refractory Multiple Myeloma

July 17th 2020

Daratumumab With Carfilzomib in Frontline Multiple Myeloma

July 17th 2020

Management of Relapsed/Refractory Multiple Myeloma

July 17th 2020

Maintenance Therapy Approaches in Multiple Myeloma

July 17th 2020

MRD Monitoring in Multiple Myeloma

July 17th 2020

The Role of Transplant in Multiple Myeloma

July 17th 2020

Treating Transplant-Eligible and -Ineligible MM

July 17th 2020

Transplant-Ineligible Multiple Myeloma

July 17th 2020

Tolerability of Triplet Therapy in Multiple Myeloma

July 17th 2020

Frontline Triplet Therapies in Multiple Myeloma

July 17th 2020

Dr. Raje on Key Challenges Faced in Multiple Myeloma

July 11th 2020

Noopur Raje, MD, discusses the current challenges faced in the multiple myeloma treatment paradigm.

Dr. Raje on the Rationale for CAR T-Cell Therapy in Multiple Myeloma

June 29th 2020

Noopur Raje, MD, discusses the rationale for CAR T-cell therapy in multiple myeloma.